Premium
Pancreatic collagenase therapy for severe, progressive systemic sclerosis: Effect on skin and on hydroxyproline content in urine
Author(s) -
Nellas Constantine L.,
Crawford Neville,
Scherbel Arthur L.
Publication year - 1965
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196563367
Subject(s) - hydroxyproline , collagenase , scleroderma (fungus) , medicine , urinary system , urine , microbial collagenase , in vivo , progressive systemic sclerosis , skin biopsy , gastroenterology , biopsy , chemistry , pathology , enzyme , biochemistry , biology , microbiology and biotechnology , inoculation , disease
A patient with severe, progressive systemic sclerosis was treated for 7 months with AL‐0534, a pancreatic collagenase preparation. With the measurement of hydroxyproline as an index, the results of the urinary output and skin biopsy content suggested that some in vivo enzymatic hydrolysis of body collagen took place during the first 2 months of treatment. Later in the treatment program, the results reverted to pretreatment levels. The failure to maintain improvement clinically, and according to laboratory tests, could be related to several theoretic factors: antibody inactivation of the enzyme, the presence of a small amount of soluble collagen, and low dosage of AL‐0534. Further clinical study is needed to evaluate the place of collagenase in the treatment of scleroderma.